V. Stoll

发表

Development of Orally Efficacious Allosteric Inhibitors of TNFα via Fragment-Based Drug Design.

S. C. Panchal, Philip B. Cox, P. Hajduk, 2020, Journal of medicinal chemistry.

Structure of MurF from Streptococcus pneumoniae co‐crystallized with a small molecule inhibitor exhibits interdomain closure

P. Hajduk, K. Longenecker, V. Stoll, 2005, Protein science : a publication of the Protein Society.

Structure‐based Optimization of MurF Inhibitors

David D. Anderson, P. Hajduk, K. Longenecker, 2006, Chemical biology & drug design.

Thienopyrimidine ureas as novel and potent multitargeted receptor tyrosine kinase inhibitors.

K. Glaser, S. Davidsen, V. Stoll, 2005, Journal of medicinal chemistry.

Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor.

K. Glaser, S. Davidsen, V. Stoll, 2007, Journal of medicinal chemistry.

Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases.

Hua Tang, Bo Liu, Gang Liu, 2011, ACS chemical biology.

Discovery of potent inhibitors of dihydroneopterin aldolase using CrystaLEAD high-throughput X-ray crystallographic screening and structure-directed lead optimization.

Jean M. Severin, Rolf Wagner, Vincent S Stoll, 2004, Journal of medicinal chemistry.

Buffers: principles and practice.

V. Stoll, J. Blanchard, 1990, Methods in enzymology.

Design and synthesis of pyridine-pyrazolopyridine-based inhibitors of protein kinase B/Akt.

V. Stoll, Eric F. Johnson, X. Liu, 2007, Bioorganic & medicinal chemistry.

Discovery of trans-3,4'-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Crystallization and preliminary x-ray diffraction study of the flavoprotein NADH peroxidase from Streptococcus faecalis 10C1.

V. Stoll, E. Pai, J. Blanchard, 1989, The Journal of biological chemistry.

binding site A potent erythropoietin mimic human antibody interacts through a novel

V. Stoll, R. Simmer, Zhihong Liu, 2013 .

A potent erythropoietin-mimicking human antibody interacts through a novel binding site.

V. Stoll, D. Egan, R. Simmer, 2007, Blood.

Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.

V. Stoll, Eric F. Johnson, N. Soni, 2009, Journal of medicinal chemistry.

Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives.

V. Stoll, A. Molla, D. Kempf, 2008, Bioorganic & medicinal chemistry letters.

Novel a- and b-Amino Acid Inhibitors of Influenza Virus Neuraminidase

V. Stoll, V. Giranda, D. Norbeck, 2001 .

Novel α- and β-Amino Acid Inhibitors of Influenza Virus Neuraminidase

V. Stoll, V. Giranda, D. Norbeck, 2001, Antimicrobial Agents and Chemotherapy.

Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.

Ana L. Aguirre, A. Hobson, K. Sarris, 2018, Journal of medicinal chemistry.

In Vitro Selection and Characterization of Influenza A (A/N9) Virus Variants Resistant to a Novel Neuraminidase Inhibitor, A-315675

V. Stoll, A. Molla, D. Kempf, 2002, Journal of Virology.

A thioredoxin fusion protein of VanH, a D‐lactate dehydrogenase from Enterococcus faecium: Cloning, expression, purification, kinetic analysis, and crystallization

V. Stoll, E. Pai, W. Gillon, 1998, Protein science : a publication of the Protein Society.

Synthesis and structure-activity relationship of 3,4'-bispyridinylethylenes: discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Identification and structure-based drug design of cell-active inhibitors of interleukin 17A at a novel C-terminal site

Justin D Dietrich, A. Petros, P. Richardson, 2022, Scientific Reports.

A highly potent and selective farnesyltransferase inhibitor ABT-100 in preclinical studies

V. Stoll, T. Holzman, S. Muchmore, 2005, Anti-cancer drugs.

Hepatitis C NS3 protease inhibition by peptidyl-alpha-ketoamide inhibitors: kinetic mechanism and structure.

P. Richardson, V. Stoll, A. Molla, 2004, Archives of biochemistry and biophysics.

Structure of the PAPP-ABP5 complex reveals mechanism of substrate recognition

J. Jumper, V. Stoll, R. Jain, 2022, Nature Communications.

Kinetic mechanism and nucleotide specificity of NADH peroxidase.

V. Stoll, J. Blanchard, 1988, Archives of biochemistry and biophysics.

Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity.

S. J. Simpson, V. Stoll, C. Walsh, 1997, Biochemistry.

Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.

V. Stoll, S. Muchmore, S. Rosenberg, 2004, Bioorganic & medicinal chemistry letters.

Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.

V. Stoll, A. Molla, D. Kempf, 2011, Bioorganic & medicinal chemistry letters.

Oximinoarylsulfonamides as potent HIV protease inhibitors.

V. Stoll, D. Kempf, J. Randolph, 2005, Bioorganic & medicinal chemistry letters.

Benzimidazolones and indoles as non-thiol farnesyltransferase inhibitors based on tipifarnib scaffold: synthesis and activity.

V. Stoll, S. Rosenberg, H. Sham, 2005, Bioorganic & medicinal chemistry letters.

Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.

V. Stoll, S. Rosenberg, N. Lin, 2005, Bioorganic & medicinal chemistry letters.

Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.

Jonathan Greer, V. Stoll, J. Greer, 2003, Biochemistry.

Buffers: principles and practice.

V. Stoll, J. Blanchard, 1990, Methods in enzymology.

Differences in binding modes of enantiomers of 1-acetamido boronic acid based protease inhibitors: crystal structures of gamma-chymotrypsin and subtilisin Carlsberg complexes.

V. Stoll, E. Pai, J. B. Jones, 1998, Biochemistry.

Aryl tetrahydropyridine inhibitors of farnesyltransferase: bioavailable analogues with improved cellular potency.

V. Stoll, S. Muchmore, S. Ng, 2003, Bioorganic & medicinal chemistry letters.

Synthesis and activity of 1-aryl-1'-imidazolyl methyl ethers as non-thiol farnesyltransferase inhibitors.

V. Stoll, S. Rosenberg, Gary T. Wang, 2004, Bioorganic & medicinal chemistry letters.

Insights into substrate binding by D-2-ketoacid dehydrogenases from the structure of Lactobacillus pentosus D-lactate dehydrogenase.

V. Stoll, E. Pai, M. Kimber, 1996, Structure.

Design, synthesis, and neuraminidase inhibitory activity of GS-4071 analogues that utilize a novel hydrophobic paradigm.

V. Stoll, D. Kempf, W. G. Laver, 2002, Bioorganic & medicinal chemistry letters.

Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity.

V. Stoll, Eric F. Johnson, X. Liu, 2006, Bioorganic & medicinal chemistry letters.

Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo

Yan Shi, V. Stoll, Eric F. Johnson, 2005, Molecular Cancer Therapeutics.

Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.

V. Stoll, Y. Tong, Haiying Zhang, 2004, Journal of medicinal chemistry.

Mutations Conferring Resistance to a Hepatitis C Virus (HCV) RNA-Dependent RNA Polymerase Inhibitor Alone or in Combination with an HCV Serine Protease Inhibitor In Vitro

Kent D. Stewart, Teresa Ng, Rubina Mondal, 2005, Antimicrobial Agents and Chemotherapy.

Characterization of protein kinase A phosphorylation: multi-technique approach to phosphate mapping.

A. Gunasekera, V. Stoll, C. Jakob, 2004, Analytical biochemistry.

Fragment-Based Discovery of an Apolipoprotein E4 (apoE4) Stabilizer.

Justin D Dietrich, A. Petros, V. Stoll, 2019, Journal of medicinal chemistry.

Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.

Vincent S Stoll, K. Longenecker, V. Stoll, 2006, Biochemistry.

Chemical mechanism and rate-limiting steps in the reaction catalyzed by Streptococcus faecalis NADH peroxidase.

V. Stoll, J. Blanchard, 1991, Biochemistry.

Sugar phosphate activation of the stress sensor eIF2B

V. Stoll, S. Hackett, R. Jain, 2021, Nature Communications.

A potent erythropoietin mimic human antibody interacts through a novel binding site Running titile: EPOR AB ACTIVATES THROUGH A NOVEL BINDING SITE

V. Stoll, D. Egan, R. Simmer, 2007 .

Synthesis and activity of N-acyl azacyclic urea HIV-1 protease inhibitors with high potency against multiple drug resistant viral strains.

V. Stoll, S. Vasavanonda, D. Norbeck, 2005, Bioorganic & medicinal chemistry letters.

Synthesis and antiviral activity of P1' arylsulfonamide azacyclic urea HIV protease inhibitors.

V. Stoll, S. Vasavanonda, D. Kempf, 2004, Bioorganic & medicinal chemistry letters.

Characterization of novel small-molecule NRF2 activators: Structural and biochemical validation of stereospecific KEAP1 binding.

I. Dulubova, V. Stoll, K. Swinger, 2016, Biochimica et biophysica acta.

2-Pyridyl P1'-substituted symmetry-based human immunodeficiency virus protease inhibitors (A-792611 and A-790742) with potential for convenient dosing and reduced side effects.

V. Stoll, A. Molla, D. Kempf, 2009, Journal of medicinal chemistry.

Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate

Ana L. Aguirre, A. Hobson, V. Stoll, 2018, Chembiochem : a European journal of chemical biology.

Buffers: principles and practice.

V. Stoll, J. Blanchard, 2009, Methods in enzymology.

Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.

Kent D. Stewart, Vincent S. Stoll, Jeffrey R. Huth, 2010, Bioorganic & medicinal chemistry letters.

Complex of human Melanotransferrin and SC57.32 Fab fragment reveals novel interdomain arrangement with ferric N-lobe and open C-lobe

K. Longenecker, V. Stoll, S. Vivona, 2021, Scientific reports.

Complex of human Melanotransferrin and SC57.32 Fab fragment reveals novel interdomain arrangement with ferric N-lobe and open C-lobe

K. Longenecker, V. Stoll, S. Vivona, 2021, Scientific Reports.

Structure-based characterization and optimization of novel hydrophobic binding interactions in a series of pyrrolidine influenza neuraminidase inhibitors.

Vincent S Stoll, A. C. Krueger, V. Stoll, 2005, Journal of medicinal chemistry.

Syntheses of potent, selective, and orally bioavailable indazole-pyridine series of protein kinase B/Akt inhibitors with reduced hypotension.

V. Stoll, G. Gintant, Eric F. Johnson, 2007, Journal of medicinal chemistry.

X-ray crystallographic structure of ABT-378 (lopinavir) bound to HIV-1 protease.

V. Stoll, R. Simmer, D. Norbeck, 2002, Bioorganic & medicinal chemistry.

Structure of human DPEP3 in complex with the SC-003 antibody Fab fragment reveals basis for lack of dipeptidase activity.

K. Longenecker, V. Stoll, S. Vivona, 2020, Journal of structural biology.

Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability.

V. Stoll, Y. Tong, Haiying Zhang, 2003, Bioorganic & medicinal chemistry letters.

Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.

V. Stoll, D. Kempf, T. Sowin, 2005, Bioorganic & medicinal chemistry letters.

Design and characterization of an engineered gp41 protein from human immunodeficiency virus-1 as a tool for drug discovery

Kevin Harris, Kent D. Stewart, Kevin Steffy, 2007, J. Comput. Aided Mol. Des..